Volitionrx LTD Form 4 insider transactions

VolitionRx Ltd's Group Chief Marketing Officer, Ann-Louise Batchelor, received 27,400 restricted stock units as compensation, vesting through early 2026.

VolitionRx's CEO of Volition Veterinary, Salvatore Thomas Butera, reported an acquisition of 33,991 restricted stock units and a disposition of 99,350 common shares.

VolitionRx's Chief Medical Officer, Andrew Retter, received 19,524 restricted stock units as part of his compensation, aligning his interests with shareholders.

VolitionRx's General Counsel, Nicholas Plummer, was awarded 24,031 restricted stock units as part of his compensation, vesting through early 2026.

Ethel Rubin, a Director at VolitionRx Ltd., received 17,424 restricted stock units as compensation, aligning her interests with shareholders.

Jasmine Kway, CEO of VolitionRx, receives 12,507 restricted stock units (RSUs) in lieu of cash compensation.

VolitionRx's Chief Commercial Officer, Gael Forterre, received 9,727 restricted stock units as compensation, vesting through early 2026.

VolitionRx Director Guy Archibald Innes acquired 78,125 shares of common stock at $0.64 per share in a registered direct offering.

VolitionRx Ltd. President and CEO Cameron John Reynolds acquired 78,125 shares of common stock at $0.64 per share in a registered direct offering.

VolitionRx's CEO of Volition Veterinary, Salvatore Thomas Butera, reported a disposition of 6,393 common shares for tax withholding related to restricted stock unit vesting.

VolitionRx's Chief Medical Officer, Andrew Retter, settled tax obligations on vested restricted stock units through a share withholding transaction, not a sale.

VolitionRx's Group Chief Marketing Officer, Ann-Louise Batchelor, had 8,620 shares withheld for tax obligations related to restricted stock unit settlement.

VolitionRx General Counsel Nicholas Plummer's Form 4 filing details the disposition of 4,451 shares to cover tax obligations on restricted stock units.

VolitionRx's Chief Commercial Officer, Gael Forterre, reported a change in beneficial ownership related to tax withholding on restricted stock units.

VolitionRx Secretary Rodney Rootsaert's Form 4 filing details the withholding of 4,279 shares for tax obligations related to RSU settlement.

VolitionRx's Chief Financial Officer, Terig Hughes, was granted 100,000 restricted stock units tied to future stock price performance and time-based vesting.

VolitionRx Ltd.'s President and CEO, Cameron John Reynolds, was granted 200,000 restricted stock units under the company's 2024 Stock Incentive Plan.

A recent SEC Form 4 filing reveals that VolitionRx's GC, Nicholas Plummer, will have 5,417 shares of common stock withheld by the company in July 2025 to cover tax obligations related to the settlement of restricted stock units.

VolitionRx Ltd.'s Secretary, Rodney Gerard Rootsaert, settled tax withholding obligations for restricted stock units by having 3,066 shares of common stock retained by the company.

VolitionRx's Chief Commercial Officer, Gael Forterre, reported a disposition of 1,996 shares of common stock to satisfy tax withholding obligations related to restricted stock unit settlement.

VolitionRx's Group Chief Marketing Officer, Ann-Louise Batchelor, settled 13,143 restricted stock units, resulting in 6,177 shares being withheld by the company to cover tax obligations at a price of $0.7679 per share.

Salvatore Thomas Butera, CEO of Volition Veterinary, reported a transaction involving the withholding of 4,462 shares of VolitionRx common stock to cover tax obligations related to restricted stock unit settlement.

VolitionRx's Chief Medical Officer, Andrew Retter, had 4,401 shares of common stock withheld by the company to cover tax obligations related to the settlement of restricted stock units.

VolitionRx Ltd.'s President and CEO, Cameron John Reynolds, increased his direct beneficial ownership by purchasing 12,500 shares of common stock at $0.5898 per share.

VolitionRx Ltd. Director Guy Archibald Innes has increased his direct beneficial ownership in the company by purchasing 20,000 shares of common stock at $0.5386 per share.

VolitionRx Ltd.'s Chief Financial Officer, Terig Hughes, was awarded 17,406 restricted stock units on June 1, 2025, as part of the company's 2015 Stock Incentive Plan.

VolitionRx Ltd's Group Chief Marketing Officer, Ann-Louise Batchelor, was awarded 18,341 restricted stock units on June 1, 2025, as part of her compensation.

VolitionRx Ltd.'s Chief Medical Officer, Andrew Retter, was awarded 13,069 restricted stock units as compensation, with 4,598 shares subsequently withheld by the company to cover tax obligations.

VolitionRx Ltd.'s Chief Scientific Officer, Jacob Vincent Micallef, reported a routine disposition of 21,526 common shares to cover tax obligations related to the settlement of restricted stock units.

VolitionRx Ltd. Director Ethel Rubin was awarded 11,983 restricted stock units (RSUs) on June 1, 2025, as non-cash compensation under the company's 2015 Stock Incentive Plan.